To determine whether the individual infused clonotypes with TEM characteristics had evolved in vivo to include alternate subsets (TCM or TTD), PBMC obtained at ~100 days from Pts. 10, 11, 12 and 24, who were selected based on TTCR-C4 persistence and sample availability, were flow-sorted for TEM, TCM or TTD tet+ cells, and the clonotypes comprising each subset were determined.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.